Minimal Residual Disease Eradication with Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia

Recurrent translocations, t(8;21) or inv(16), in core binding factor acute myeloid leukemia (CBF-AML) are amenable to monitoring for minimal residual disease (MRD) with reverse transcriptase polymerase chain reaction (RTPCR). Despite a favorable prognosis, disease relapse remains the single cause of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Hematol
Autors principals: Ragon, Brittany Knick, Daver, Naval, Garcia-Manero, Guillermo, Ravandi, Farhad, Cortes, Jorge, Kadia, Tapan, Oran, Betul, Ohanian, Maro, Ferrajoli, Alessandra, Pemmaraju, Naveen, Kantarjian, Hagop M, Borthakur, Gautam
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5779853/
https://ncbi.nlm.nih.gov/pubmed/28494506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24782
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars